FDA Approves Levoleucovorin for Treatment in Osteosarcoma, Colorectal Cancer

October 26, 2018 – The U.S. Food and Drug Administration (FDA) recently approved levoleucovorin injection, a folate analog, for three indications: rescue after high-dose methotrexate therapy in patients with osteosarcoma; diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination; and the treatment of patients with metastatic colorectal cancer in combination with fluorouracil. Levoleucovorin is contraindicated … (leggi tutto)